Inter-Individual Variations: A Challenge for the Standardisation of Complement Activation Assays

Abstract

Dorelia Lipsa, Ana Ruiz Moreno, Cloé Desmet, Ivana Bianchi, Otmar Geiss, Pascal Colpo, Susanne Bremer-Hoffmann European Commission, Joint Research Centre (JRC), Ispra, ItalyCorrespondence: Susanne Bremer-Hoffmann, Email [email protected]: The role of the human immune system in pathologic responses to chemicals including nanomaterials was identified as a gap in current hazard assessments. However, the complexity of the human immune system as well as interspecies variations make the development of predictive toxicity tests challenging. In the present study, we have analysed to what extent fluctuations of the complement system of different individuals will have an impact on the standardisation of immunological tests.Methods: We treated commercially available pooled sera (PS) from healthy males, individual sera from healthy donors and from patients suffering from cancer, immunodeficiency and allergies with small molecules and liposomes. Changes of iC3b protein levels measured in enzyme-linked immunosorbent assays served as biomarker for complement activation.Results: The level of complement activation in PS differed significantly from responses of individual donors (p < 0.01). Only seven out of 32 investigated sera from healthy donors responded similarly to the pooled serum. This variability was even more remarkable when investigating the effect of liposomes on the complement activation in sera from donors with pre-existing pathologies. Neither the 26 sera of donors with allergies nor sera of 16 donors with immunodeficiency responded similar to the PS of healthy donors. Allergy sufferers showed an increase in iC3b levels of 4.16-fold changes when compared to PS treated with liposomes.Discussion: Our studies demonstrate that the use of pooled serum can lead to an over- or under-estimation of immunological response in particular for individuals with pre-existing pathologies. This is of high relevance when developing medical products based on nanomaterials and asks for a review of the current practice to use PS from healthy donors for the prediction of immunological effects of drugs in patients. A better understanding of individual toxicological responses to xenobiotics should be an essential part in safety assessments.Graphical Abstract: Keywords: inter-individual variability, complement activation, liposomes, standardisation, patients with pre-existing pathologies, healthy donors

Keywords

• inter-individual variability
• complement activation
• liposomes
• standardization
• patients with preconditions
• healthy donors